The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Drotrecogin Alfa (Activated) in Adults with Septic Shock
Abstract
BACKGROUND: There have been conflicting reports on the efficacy of recombinant human activated protein C, or drotrecogin alfa (activated) (DrotAA), for the treatment of patients with septic shock. METHODS: In this randomized, double-blind, placebo-controlled, multicenter trial, we assigned 1697 patients with infection, systemic inflammation, and shock who were receiving fluids and vasopressors above a threshold dose for 4 hours to receive either DrotAA (at a dose of 24 μg per kilogram of body weight per hour) or placebo for 96 hours. The primary outcome was death from any cause 28 days after randomization. RESULTS: At 28 days, 223 of 846 patients (26.4%) in the DrotAA group and 202 of 834 (24.2%) in the placebo group had died (relative risk in the DrotAA group, 1.09; 95% confidence interval [CI], 0.92 to 1.28; P=0.31). At 90 days, 287 of 842 patients (34.1%) in the DrotAA group and 269 of 822 (32.7%) in the placebo group had died (relative risk, 1.04; 95% CI, 0.90 to 1.19; P=0.56). Among patients with severe protein C deficiency at baseline, 98 of 342 (28.7%) in the DrotAA group had died at 28 days, as compared with 102 of 331 (30.8%) in the placebo group (risk ratio, 0.93; 95% CI, 0.74 to 1.17; P=0.54). Similarly, rates of death at 28 and 90 days were not significantly different in other predefined subgroups, including patients at increased risk for death. Serious bleeding during the treatment period occurred in 10 patients in the DrotAA group and 8 in the placebo group (P=0.81). CONCLUSIONS: DrotAA did not significantly reduce mortality at 28 or 90 days, as compared with placebo, in patients with septic shock. (Funded by Eli Lilly; PROWESS-SHOCK ClinicalTrials.gov number, NCT00604214.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The epidemiology of sepsis in the United States from 1979 through 2000
Martin, G. S., Mannino, D. M., Eaton, S., & Moss, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022139 · Cited by 5,841
Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock
Russell, J. A., Walley, K. R., Singer, J., Gordon, A. C., Hébert, P. C., Cooper, D. J., Holmes, C. L., Mehta, S., Granton, J. T., Storms, M. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa067373 · Cited by 1,924
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*
Rice, T. W., Wheeler, A. P., Bernard, G. R., Vincent, J.-L., Angus, D. C., Aikawa, N., Demeyer, I., Sainati, S., Amlot, N., Cao, C., et al. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181e7c5c9 · Cited by 512
Cited by
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationSurviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Self-citationCecconi, M., Evans, L., Levy, M., & Rhodes, A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30696-2 · Cited by 2,254
Self-citationThe immunopathology of sepsis and potential therapeutic targets
van der Poll, T., van de Veerdonk, F. L., Scicluna, B. P., & Netea, M. G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.36 · Cited by 1,957
The acute respiratory distress syndrome
Matthay, M. A., Ware, L. B., & Zimmerman, G. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60331 · Cited by 1,706
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
Seymour, C. W., Kennedy, J. N., Wang, S., Chang, C.-C. H., Elliott, C. F., Xu, Z., Berry, S., Clermont, G., Cooper, G., Gomez, H., et al. (2019) · JAMA · doi:10.1001/jama.2019.5791 · Cited by 1,567
Kaukonen, K.-M., Bailey, M., Suzuki, S., Pilcher, D., & Bellomo, R. (2014) · JAMA · doi:10.1001/jama.2014.2637 · Cited by 1,459
Komorowski, M., Celi, L. A., Badawi, O., Gordon, A. C., & Faisal, A. A. (2018) · Nature Medicine · doi:10.1038/s41591-018-0213-5 · Cited by 1,290
High versus low blood-pressure target in patients with septic shock.
Asfar, P., Meziani, F., Hamel, J.-F., Grelon, F., Megarbane, B., Anguel, N., Mira, J.-P., Dequin, P.-F., Gergaud, S., Weiss, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312173 · Cited by 1,239
Roberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046
Adjunctive glucocorticoid therapy in patients with septic shock.
Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., Billot, L., Correa, M., Glass, P., Harward, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705835 · Cited by 1,037
Self-citationWhy have clinical trials in sepsis failed?
Marshall, J. C. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.01.007 · Cited by 805
Self-citationPhase I safety trial of intravenous ascorbic acid in patients with severe sepsis.
Nursing, M. R. I. C. U., Fowler, A. A., Syed, A. A., Knowlson, S., Sculthorpe, R., Farthing, D., DeWilde, C., Farthing, C. A., Larus, T. L., Martin, E., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-32 · Cited by 573
Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives
Dumont, J., Euwart, D., Mei, B., Estes, S., & Kshirsagar, R. (2016) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1084266 · Cited by 483
Fink, M. P. (2014) · Virulence · doi:10.4161/viru.26083 · Cited by 391
Roberts, J. A., Abdul-Aziz, M.-H., Davis, J. S., Dulhunty, J. M., Cotta, M. O., Myburgh, J., Bellomo, R., & Lipman, J. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0024oc · Cited by 379
Damiani, E., Donati, A., Serafini, G., Rinaldi, L., Adrario, E., Pelaia, P., Busani, S., & Girardis, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125827 · Cited by 275
Activated protein C: biased for translation
Griffin, J. H., Zlokovic, B. V., & Mosnier, L. O. (2015) · Blood · doi:10.1182/blood-2015-02-355974 · Cited by 257
Leone, M., Bechis, C., Baumstarck, K., Lefrant, J.-Y., Albanèse, J., Jaber, S., Lepape, A., Constantin, J.-M., Papazian, L., Bruder, N., et al. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3411-8 · Cited by 243
Timing and causes of death in septic shock
Daviaud, F., Grimaldi, D., Dechartres, A., Charpentier, J., Geri, G., Marin, N., Chiche, J.-D., Cariou, A., Mira, J.-P., & Pène, F. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0058-8 · Cited by 234
Amelioration of sepsis by TIE2 activation–induced vascular protection
Han, S., Lee, S.-J., Kim, K. E., Lee, H. S., Oh, N., Park, I., Ko, E., Oh, S. J., Lee, Y.-S., Kim, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9260 · Cited by 203
Risk of subsequent sepsis within 90 days after a hospital stay by type of antibiotic exposure.
Baggs, J., Jernigan, J. A., Halpin, A. L., Epstein, L., Hatfield, K. M., & McDonald, L. C. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix947 · Cited by 190
The Emerging Role of Vitamin C as a Treatment for Sepsis
Kashiouris, M. G., L’Heureux, M., Cable, C. A., Fisher, B. J., Leichtle, S. W., & Fowler, A. A. (2020) · Nutrients · doi:10.3390/nu12020292 · Cited by 177
Timing of vasopressor initiation and mortality in septic shock: a cohort study
Beck, V., Chateau, D., Bryson, G. L., Pisipati, A., Zanotti, S., Parrillo, J. E., Kumar, A., & The Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group (2014) · Critical Care · doi:10.1186/cc13868 · Cited by 161
de Grooth, H.-J., Postema, J., Loer, S. A., Parienti, J.-J., Oudemans-van Straaten, H. M., & Girbes, A. R. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5134-8 · Cited by 92
Kuhn, S.-O., Meissner, K., Mayes, L. M., & Bartels, K. (2018) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000549 · Cited by 82
Glutamine and Antioxidants in Critically Ill Patients
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1306658 · Cited by 56
Bradford, M. A., Lindenauer, P. K., Wiener, R. S., & Walkey, A. J. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000403 · Cited by 43
Driving blind: Instituting SEP-1 without high quality outcomes data
Wang, J., Strich, J. R., Applefeld, W. N., Sun, J., Cui, X., Natanson, C., & Eichacker, P. Q. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.12.100 · Cited by 34
Metadata
- Authors
- Ranieri, V. M., Thompson, B. T., Barie, P. S., Dhainaut, J.-F., Douglas, I. S., Finfer, S., Gårdlund, B., Marshall, J. C., Rhodes, A., Artigas, A., Payen, D., Tenhunen, J., Al-Khalidi, H. R., Thompson, V., Janes, J., Macias, W. L., Vangerow, B., & Williams, M. D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-05-31
- Volume
- 366
- Issue
- 22
- Pages
- 2055-2064
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2104825124
- Cited by
- 1,309
- References
- 3
- FWCI
- 102.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
